Radiotherapy could spare bladder cancer patients surgery

October 1, 2013, Cancer Research UK
Radiotherapy could spare bladder cancer patients surgery

Radiotherapy is an effective treatment for aggressive bladder cancer and could spare patients surgery that removes the whole bladder, according to a study published in this month's International Journal of Radiation Oncology Biology Physics.

The Cancer Research UK study found that two different approaches to giving controlled the disease and had a low risk of severe side effects.

This part of the BC2001 radiotherapy study, led by researchers at The Institute of Cancer Research, London, and the University of Birmingham, compared giving radiotherapy to the whole bladder with targeted radiotherapy focused on the tumour.

Both types of treatment prevented the tumour from returning for over 60 per cent of patients for at least two years. And for many whose disease returned, it was not aggressive and only needed local treatment.

After five years of follow-up the survival rates were around 40 per cent for both radiotherapy approaches, a figure comparable to patients who have surgery to remove their bladder. In addition, patients receiving either type of radiotherapy had a low risk of severe side effects.

The standard treatment for aggressive is to remove the bladder. This can cause severe side effects and usually results in patients wearing a plastic bag to collect urine.

Dr Robert Huddart, lead investigator of the study based at The Institute of Cancer Research, London, said: "Our study was part of the largest ever clinical trial of radiotherapy in bladder cancer and shows that patients with the disease can be treated effectively with radiotherapy. With similar success rates to surgery and fewer side effects whilst allowing patients to retain a functioning bladder, radiotherapy should be seen as an alternative to surgery.

"The introduction of image guided radiotherapy and more sophisticated ways of giving radiotherapy will hopefully further reduce any that patients experience."

Kate Law, director of clinical research at Cancer Research UK, said: "Previous results from this trial changed how doctors treat bladder cancer, showing that giving patients chemotherapy and radiotherapy is better than radiotherapy alone. Many thousands of take part in Cancer Research UK-funded clinical trials every year, and it's only by carrying out studies like this that we can test different approaches to find the most effective and safest treatments."

Explore further: Bladder cancer patients over 70 less likely to get curative treatment

More information: Huddart, R et al Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004) International Journal of Radiation Oncology biology physics (2013)

Related Stories

Bladder cancer patients over 70 less likely to get curative treatment

April 17, 2013
(Medical Xpress)—Older bladder cancer patients are less likely than younger patients to receive treatments intended to cure their disease such as surgery to remove the bladder or radiotherapy. But this difference cannot ...

Accelerated radiotherapy more efficient than current practice

September 4, 2013
Radiotherapy with or without chemotherapy is increasingly being used in the curative treatment for un-resected non-small cell lung cancer (NSCLC). But, until now, researchers had not looked at the cost-effectiveness of the ...

Adding chemo to radiotherapy halves risk of deadly bladder cancer returning

April 23, 2012
(Phys.org) -- Bladder cancer patients given low doses of chemotherapy combined with radiotherapy were nearly 50 per cent less likely to relapse with the most lethal form of the disease compared to patients given radiotherapy ...

Breast conserving treatment with radiotherapy reduces risk of local recurrence

September 18, 2013
Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). ...

Multi-tasking imatinib boosts radiotherapy for bladder tumours

March 4, 2013
Cancer drug imatinib (Glivec) could boost radiotherapy treatment to destroy bladder cancer that has spread to the bladder wall, reveals research published in Cancer Research.

Recommended for you

Researchers discover novel mechanism linking changes in mitochondria to cancer cell death

February 20, 2018
To stop the spread of cancer, cancer cells must die. Unfortunately, many types of cancer cells seem to use innate mechanisms that block cancer cell death, therefore allowing the cancer to metastasize. While seeking to further ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.